From: Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow
Regulator | Cell type | Target | Action | Mechanism | Citation |
---|---|---|---|---|---|
Intracellular factors | |||||
USP6 | Mouse preosteoblast cells | JAK1 | Protein degradation | Directly binding, leading to deubiquitination and stabilization of JAK1 | [92] |
TRIM27 | HEK293, HeLa | JAK1 | Formation of a complex | Directly binding, increasing the binding ability of JAK1 | [93] |
ALEX1 | AGS | JAK1 | Functional activation | Increasing the phosphorylation level | [94] |
APLNR | HEK293T, A375 | JAK1 | Formation of a complex | Directly binding | [95] |
BRCA1 | EcR-293 | JAK1 | Regulation of gene expression | Transcriptionally upregulating JAK1 | [96] |
CDK1 | A549, 1792 | JAK1 | Functional activation | Increasing the phosphorylation level | [97] |
CISH | Murine NK cells | JAK1 | Protein degradation | Directly binding, leading to ubiquitination and degradation of JAK1 | [98] |
c-KIT | HepG2, SNU398, SNU449 | JAK1 | Functional activation | Increasing the phosphorylation level | [99] |
TJP1 | Multiple myeloma cells | JAK1 | Functional activation | Decreasing the phosphorylation level in an EGFR-dependent manner | [100] |
HIF-1α | Glioma stem-like cells | JAK1 | Functional activation | Increasing the phosphorylation level | [90] |
SgK223 | Pancreatic ductal epithelial cells | JAK1 | Functional activation | Increasing the phosphorylation level | [101] |
LDL | PC‐3, LNCaP, MIA PaCa‐2, PANC‐1 | JAK1 | Functional activation | Increasing the phosphorylation level | [102] |
MUC1-C | ZR-75–1, MCF-7, MCF-10A | JAK1 | Formation of a complex | Directly binding, increasing the binding ability of JAK1 | [103] |
Annexin A1 | EpH4 | TYK2 | Functional repression | Decreasing the phosphorylation level | [104] |
CTLA4 | Lymphoma cells and multiple myeloma cells | TYK2 | Functional activation | Increasing the phosphorylation level | [105] |
MEOX1 | MCF-10A, MCF-7, T-47D | TYK2 | Regulation of gene expression | Upregulating TYK2 | [106] |
Exogenic factors | |||||
AH057 | HeLa, DU145, HepG2 | JAK1 | Functional repression | Decreasing the phosphorylation level | [107] |
Sorafenib | U87, U251 | JAK1 | Functional repression | Decreasing the phosphorylation level | [108] |
Maraviroc | SUP-B15 | JAK1 | Functional repression | Decreasing the phosphorylation level | [109] |
CDDO-Me | HeLa, MDA-MB-468 | JAK1 | Functional repression | Decreasing the phosphorylation level | [110] |
Myricetin | JB6 | JAK1 | Functional repression | Decreasing the phosphorylation level | [111] |
Leptin | H292, MCF7, MDA-MB-231 | JAK1 | Functional activation | Increasing the phosphorylation level | [112] |
Triptolide | SW480, Caco 2 | JAK1 | Regulation of gene expression | Downregulating JAK1 | [113] |
Regorafenib | MEL-RM | JAK1 | Functional repression | Decreasing the phosphorylation level | [114] |
Oxymatrine | A549 | JAK1 | Functional repression | Decreasing the phosphorylation level | [115] |
4HPR | UMSCC22B | JAK1 | Regulation of gene expression | Upregulating JAK1 | [116] |
HO-3867 | Ovarian cancer cells | JAK1 | Functional repression | Decreasing the phosphorylation level | [117] |
Fraxinellone | A549 | JAK1 | Functional repression | Decreasing the phosphorylation level | [118] |
Formononetin | U266, RPMI 8226 | JAK1 | Functional repression | Decreasing the phosphorylation level | [119] |
Cirsiliol | Esophageal cancer cells | TYK2 | Formation of a complex | Directly binding | [89] |
PU-H71 | MDA-MB-231 | TYK2 | Regulation of gene expression | Downregulating TYK2 | [120] |
17-Hydroxy-jolkinolide B | HepG2 | TYK2 | Regulation of gene expression | Downregulating TYK2 | [121] |